CoChat

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Open access
Averna, Maurizio, Banach, Maciej, Bruckert, Eric, Drexel, Heinz, Farnier, Michel, Gaita, Dan, Magni, Paolo, März, Winfried, Masana, Luis, Mello e Silva, Alberto, Reiner, Zeljko, Ros, Emilio, Vrablik, Michal, Zambon, Alberto, Zamorano, Jose L., Stock, Jane K., Tokgözoğlu, Lale S., Catapano, Alberico L. · 2021 · Atherosclerosis
Cited by 137

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND AIMS This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients. METHODS Evidence-based review. RESULTS Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus. CONCLUSIONS This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2021.03.039

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 50

  1. Béliard, 2018, High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French Familial Hypercholesterolemia Registry, Atherosclerosis, 277, 334, 10.1016/j.atherosclerosis.2018.08.010 · DOI
  2. Vrablik, 2018, Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: results of the PLANET registry, Atherosclerosis, 277, 355, 10.1016/j.atherosclerosis.2018.08.008 · DOI
  3. Ray, 2020, DA VINCI study, EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study, Eur J Prev Cardiol
  4. Kotseva, 2019, Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry, Eur J Prev Cardiol, 26, 824, 10.1177/2047487318825350 · DOI · Paper page
  5. De Backer, 2019, Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries, Atherosclerosis, 285, 135, 10.1016/j.atherosclerosis.2019.03.014 · DOI · Paper page
  6. Gencer, 2015, Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes, Atherosclerosis, 239, 118, 10.1016/j.atherosclerosis.2014.12.049 · DOI
  7. Gencer, 2020, Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: a contemporary analysis from the SPUM-ACS cohort, Int. J. Cardiol., 303, 8, 10.1016/j.ijcard.2019.12.011 · DOI
  8. Drexel, 2020, An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: barriers to be overcome, Eur Heart J Cardiovasct Pharmacother, 6, 115, 10.1093/ehjcvp/pvz079 · DOI
  9. Penson, 2020, LDL-C: lower is better for longer-even at low risk, BMC Med., 18, 320, 10.1186/s12916-020-01792-7 · DOI · Paper page
  10. Lauridsen, 2015, Genetic variation in the cholesterol transporter NPC1L1, ischemic vascular disease and gallstone disease, Eur. Heart J., 36, 1601, 10.1093/eurheartj/ehv108 · DOI · Paper page
  11. Ference, 2019, Mendelian randomization study of ACLY and cardiovascular disease, N. Engl. J. Med., 380, 1033, 10.1056/NEJMoa1806747 · DOI · Paper page
  12. Bacquer, 2019, Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: real world evidence from clinical practice: data from the ESC-EORP EUROASPIRE V Study, Eur J Prev Cardiol
  13. Schiele, 2017, Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention, Eur J Prev Cardiol, 24, 88, 10.1177/2047487317706586 · DOI
  14. Dyrbus, 2020, Lipid disorders therapy in patients with chronic coronary syndrome and myocardial infarction. Experts opinion of the polish society of Cardiology (PCS) and the polish lipid associatin (PoLA), Kardiol. Pol.
  15. Amarenco, 2020, Treat Stroke to Target Investigators. A comparison of two LDL cholesterol targets after ischemic stroke, N. Engl. J. Med., 382, 9, 10.1056/NEJMoa1910355 · DOI · Paper page
  16. Ballantyne, 2019, Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy, Eur J Prev Cardiol
  17. Annemans, 2018, 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies, Eur. Heart J., 39, 2546, 10.1093/eurheartj/ehx710 · DOI · Paper page
  18. Carnicelli, 2020, In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG, Ann. Intern. Med., 172, 10.7326/ACPJ202001210-003 · doi:10.7326/acpj202001210-003
  19. Goodman, 2019, Effects of alirocumab on cardiovascular events after coronary bypass surgery, J. Am. Coll. Cardiol., 74, 1177, 10.1016/j.jacc.2019.07.015 · DOI
  20. Diaz, 2020, ODYSSEY OUTCOMES Committees and Investigators. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial, Eur J Prev Cardiol
  21. Jukema, 2019, Effect of alirocumab on stroke in ODYSSEY OUTCOMES, Circulation, 140, 2054, 10.1161/CIRCULATIONAHA.119.043826 · DOI · Paper page
  22. Santos, 2020, Long-term evolocumab in patients with familial hypercholesterolemia, J. Am. Coll. Cardiol., 75, 565, 10.1016/j.jacc.2019.12.020 · DOI · Paper page
  23. Dufour, 2019, Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: results from an open-label extension of the ODYSSEY LONG TERM trial, J Clin Lipidol, 13, 138, 10.1016/j.jacl.2018.11.007 · DOI
  24. Dressel, 2019, Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: insights from the Ludwigshafen Risk and Cardiovascular Health cohort, Vasc. Pharmacol., 120, 106566, 10.1016/j.vph.2019.106566 · DOI
  25. Banach, 2020, Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia, JAMA Cardiol, 5, 1, 10.1001/jamacardio.2020.2314 · DOI · Paper page
  26. Alder, 2020, A meta-analysis assessing additional LDL-C reduction from addition of a bile acid sequestrant to statin therapy, Am. J. Med., S0002–9343, 30372
  27. Handelsman, 2011, Role of bile acid sequestrants in the treatment of type 2 diabetes, Diabetes Care, 34, S244, 10.2337/dc11-s237 · DOI · Paper page
  28. Sabatine, 2018, Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis, JAMA Cardiol, 3, 823, 10.1001/jamacardio.2018.2258 · DOI · Paper page
  29. Koren, 2019, Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia, J. Am. Coll. Cardiol., 74, 2132, 10.1016/j.jacc.2019.08.1024 · DOI · Paper page
  30. Gürgöze, 2019, Adverse events associated with PCSK9 inhibitors: a real-world experience, Clin. Pharmacol. Ther., 105, 496, 10.1002/cpt.1193 · DOI · Paper page
  31. Nordestgaard, 2013, Eur. Heart J., 34, 3478, 10.1093/eurheartj/eht273 · DOI · Paper page
  32. Schmidt, 2018, Atherosclerosis, 277, 314, 10.1016/j.atherosclerosis.2018.08.050 · DOI
  33. Baum, 2019, Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: results of the randomized, controlled, open label DE LAVAL study, J Clin Lipidol, 13, 901, 10.1016/j.jacl.2019.10.003 · DOI
  34. Moriarty, 2016, Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial, Eur. Heart J., 37, 3588, 10.1093/eurheartj/ehw388 · DOI · Paper page
  35. Cicero, 2017, Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Nutr. Rev., 75, 731, 10.1093/nutrit/nux047 · DOI · Paper page
  36. Cofán, 2019, Use of plant sterol and stanol fortified foods in clinical practice, Curr. Med. Chem., 26, 6691, 10.2174/0929867325666180709114524 · DOI
  37. Penson, 2020, The role of nutraceuticals in the optimization of lipid-lowering therapy in high-risk patients with dyslipidaemia, Curr. Atherosclerosis Rep., 22, 67, 10.1007/s11883-020-00887-z · DOI
  38. Aggett, 2018, Scientific opinion on the safety of monacolins in red yeast rice, EFSA Journal
  39. Banach, 2019, The role of red yeast rice (RYR) supplementation in plasma cholesterol control: a review and expert opinion, Atherosclerosis Suppl., 39, e1, 10.1016/j.atherosclerosissup.2019.08.023 · DOI
  40. Fogacci, 2019, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP). Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials, Pharmacol. Res., 143, 1, 10.1016/j.phrs.2019.02.028 · DOI · Paper page
  41. 2017, Reiner Ž Hypertriglyceridaemia and risk of coronary artery disease, Nat. Rev. Cardiol., 14, 401, 10.1038/nrcardio.2017.31 · DOI · Paper page
  42. Penson, 2019, Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study, Cardiovasc. Res., 115, 204, 10.1093/cvr/cvy198 · DOI
  43. Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
  44. Ginsberg, 2011, The ACCORD (action to control cardiovascular risk in diabetes) lipid trial: what we learn from subgroup analyses, Diabetes Care, 34, S107, 10.2337/dc11-s203 · DOI · Paper page
  45. Bernelot Moens, 2017, Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans, Arterioscler. Thromb. Vasc. Biol., 37, 969, 10.1161/ATVBAHA.116.308834 · DOI · Paper page
  46. Norata, 2007, Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies, Atherosclerosis, 193, 321, 10.1016/j.atherosclerosis.2006.09.015 · DOI
  47. Sacks, 2014, Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries, Circulation, 129, 999, 10.1161/CIRCULATIONAHA.113.002529 · DOI · Paper page
  48. Sharma, 2020, Effects of omega-3 fatty acids on major adverse cardiovascular events: what matters most: the drug, the dose, or the placebo?, J. Am. Med. Assoc., 10.1001/jama.2020.22387 · DOI
  49. Keech, 2007, FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, Lancet, 370, 1687, 10.1016/S0140-6736(07)61607-9 · DOI · Paper page
  50. Catapano, 2020, Insights from ORION studies: focus on inclisiran safety, Cardiovasc. Res.

Cited by

See all 137

Metadata

Authors
Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., Reiner, Z., Ros, E., Vrablik, M., Zambon, A., Zamorano, J. L., Stock, J. K., Tokgözoğlu, L. S., & Catapano, A. L.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2021-05
Volume
325
Pages
99-109
ISSN
0021-9150 (ISSN-L)
OpenAlex
W3153390842
Cited by
137
References
63
FWCI
22.45
Type
journal article
Language
en
Open access
green
Funders
Instituto de Salud Carlos III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2021.03.039
The paper
Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., Reiner, Z., Ros, E., Vrablik, M., Zambon, A., Zamorano, J. L., Stock, J. K., Tokgözoğlu, L. S., & Catapano, A. L. (2021). Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2021.03.039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.